XRHealth acquires Swing Therapeutics to build the largest extended reality digital therapeutic platform for chronic pain

Industry Background: The Digital Therapeutics Gap in Chronic Pain

Chronic pain affects approximately 50 million adults in the United States, including over 10 million with fibromyalgia, yet there has long been a lack of effective and accessible non-pharmacological interventions. Traditional treatment relies on multidisciplinary collaboration but is limited by shortages of specialists and low patient adherence. Digital therapeutics (DTx), with their scalable and data-driven characteristics, are emerging as a potential solution to fill this gap. However, DTx face two core challenges: the rigor of clinical evidence and payer acceptance.

In this context, XRHealth, an extended reality (XR) clinical innovation company, has acquired Swing Therapeutics, a digital therapeutics pioneer, aiming to build an end-to-end chronic pain management platform that integrates immersive technology, evidence-based behavioral interventions, and insurance reimbursement.

Key Progress: Integrating FDA-Authorized Therapy with Virtual Clinic

According to the announcement on July 15, 2026, XRHealth has officially acquired Swing Therapeutics. The core asset of the transaction is Swing’s flagship product, Stanza®—the first prescription digital behavioral therapy to receive FDA De Novo authorization for the treatment of fibromyalgia symptoms. Stanza is based on Acceptance and Commitment Therapy (ACT), and its Phase III randomized controlled trial results were published in *The Lancet*, demonstrating statistically significant improvements in pain intensity, fatigue, and depression.

Additionally, Swing Care—an interdisciplinary virtual specialty clinic led by Dr. Andrea Chadwick, an international fibromyalgia authority—has also been integrated into the platform. This clinic combines digital software with medication management monitored by physicians, offering "whole-person" care.

Eran Orr, CEO of XRHealth, stated: "The future of treatment is technology. Not as a supplement to medication, but as the medication itself—delivered via AI, monitored by licensed clinicians, reimbursed by insurance, and continuously improved through outcome data."

Market Impact: A Reimbursable Virtual Care Model

The biggest commercial differentiator of this transaction lies in its reimbursement pathway. XRHealth already operates as a licensed virtual clinic in 22 states, with coverage channels including Medicare Part B, Veterans Affairs (VA) programs, and expanded commercial insurance plans. This means partnering healthcare systems do not need to bear upfront procurement costs, and patients can directly access services through their existing insurance.

Real-world data from Swing Care’s first year of operations shows: 88.0% of patients reported significant improvement on the Patient Global Impression of Change (PGIC) scale, and over half (50.2%) rated their improvement as "much improved" or better. This data-driven evidence provides a solid foundation for value-based payment.For the industry, this model may accelerate the transition of digital therapeutics from single-point tools to integrated care platforms. Traditional competitors (such as Pear Therapeutics, which has gone bankrupt) were hindered by a lack of reimbursement pathways, while XRHealth bypassed this obstacle through a "virtual clinic + direct insurance billing" model.

Challenges and Risks

Although the platform has demonstrated clinical and commercial advantages, it still faces multiple risks. First, the penetration rate of extended reality devices among patients and long-term adherence remain to be validated; second, the FDA De Novo authorization is limited to fibromyalgia indications, and expanding to other types of chronic pain will require additional clinical trials and regulatory approvals. In addition, data privacy and security compliance (such as HIPAA) in remote monitoring require continuous investment. Payers may require larger-scale cost-effectiveness comparison data to expand coverage.

Future Outlook

Over the next 3–5 years, the integration of digital therapeutics and immersive technology will accelerate. If XRHealth can replicate its standard clinical protocol to more chronic diseases (such as low back pain, migraine) while maintaining insurance coverage, it could become a benchmark platform in chronic care. On the capital side, reimbursable digital health models are more favored by investors, and this acquisition will attract more funding into the XR+DTx track. On the regulatory side, the FDA's subsequent review of products with De Novo authorization will set industry standards.

Back to Industry Trends

The merger of XRHealth and Swing Therapeutics is not only an integration at the corporate level but also represents a key turning point for the digital health industry—from "technology validation" to "payment validation." When clinical evidence and reimbursement pathways are in place simultaneously, extended reality digital therapeutics truly have the potential to scale and disrupt traditional chronic disease care.